WallStSmart

Medtronic PLC (MDT)vsXtant Medical Holdings Inc (XTNT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 26563% more annual revenue ($35.48B vs $133.08M). MDT leads profitability with a 13.0% profit margin vs 1.3%. MDT appears more attractively valued with a PEG of 1.50. MDT earns a higher WallStSmart Score of 56/100 (C).

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0

XTNT

Hold

50

out of 100

Grade: D+

Growth: 7.3Profit: 5.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$86.58

$62.24 premium

UndervaluedFair: $24.34Overvalued
XTNTSignificantly Overvalued (-744.3%)

Margin of Safety

-744.3%

Fair Value

$0.07

Current Price

$0.56

$0.49 premium

UndervaluedFair: $0.07Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

XTNT2 strengths · Avg: 8.0/10
Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
19.0%8/10

19.0% revenue growth

Areas to Watch

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

XTNT4 concerns · Avg: 3.5/10
PEG RatioValuation
1.744/10

Expensive relative to growth rate

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$81.52M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
3.6%3/10

ROE of 3.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bull Case : XTNT

The strongest argument for XTNT centers on Price/Book, Revenue Growth. Revenue growth of 19.0% demonstrates continued momentum.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Bear Case : XTNT

The primary concerns for XTNT are PEG Ratio, EPS Growth, Market Cap. A P/E of 58.2x leaves little room for execution misses. Thin 1.3% margins leave little buffer for downturns.

Key Dynamics to Monitor

MDT profiles as a value stock while XTNT is a growth play — different risk/reward profiles.

MDT carries more volatility with a beta of 0.73 — expect wider price swings.

XTNT is growing revenue faster at 19.0% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (56/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Xtant Medical Holdings Inc

HEALTHCARE · MEDICAL DEVICES · USA

Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. The company is headquartered in Belgrade, Montana.

Want to dig deeper into these stocks?